
How a Parkinson's Watch Expanded to Support SaMD/DTx Offerings
AT GLANCE
The Story
An international digital health tech organization offers a novel Remote Patient Monitoring watch that tracks biomarkers for Parkinson’s disease patients. They experienced hurdles in gaining adoption in the U.S. market and were looking for additional avenues to utilize their FDA-approved device.
The Ask
The client consulted Decimal.health to identify a beachhead use case for their novel Parkinson’s disease wearable. They aimed to reach a goal of $25M in revenue within 5 years post-launch in the U.S. market and were open to device modification and adjustment to better fit the ideal business model.
THE APPROACH
To identify an ideal route to market, we initially created a journey map of Parkinson’s disease and identified stages of Parkinson’s where the wearable provided the highest utility. Afterward, we determined the ideal target users and care settings for this digital MedTech company. Some options included health systems, clinics, medical device companies, and pharma companies.
Following the market analysis, we interviewed expert stakeholders to determine the need for the product, the feasibility of launch in the applicable care setting, and the likelihood of reaching client goals. With a thorough understanding of these factors, we were able to recommend an ideal use case and care setting that matched market and client needs.
RESULTS
From our recommendation, the client decided to pursue a SaMD classification for their medical wearable with the goal of eventually becoming a DTx platform. We saw great potential in their device to work complementary with pharmaceutical drugs and become a treatment adjacent digital therapeutic. We are currently working with this company to selectively target partnering pharma companies for their device.
THE TEAM

